|
|
 Previous Article | Table of Contents | Next Article 
Natural Killer and B-Lymphoid Potential in CD34+ Cells
Derived From Embryonic Stem Cells Differentiated in the Presence of
Vascular Endothelial Growth Factor
Naoki Nakayama,
Inghwa Fang, and
Gary Elliott
From the Department of Cell Biology, Amgen Inc, Thousand
Oaks, CA.
Differentiation of totipotent mouse embryonic stem (ES) cells to
various lymphohematopoietic cells is an in vitro model of the
hematopoietic cell development during embryogenesis. To understand this
process at cellular levels, differentiation intermediates were
investigated. ES cells generated progeny expressing CD34, which was
significantly enhanced by vascular endothelial growth factor (VEGF).
The isolated CD34+ cells were enriched for myeloid
colony-forming cells but not significantly for erythroid colony-forming
cells. When cultured on OP9 stroma cells in the presence of
interleukin-2 and interleukin-7, the CD34+ cells
developed two types of B220+ CD34
lymphocytes: CD3 cytotoxic lymphocytes and
CD19+ pre-B cells, and such lymphoid potential was highly
enriched in the CD34+ population. Interestingly, the
cytotoxic cells expressed the natural killer (NK) cell markers, such as
NKR-P1, perforin, and granzymes, classified into two types, one of
which showed target specificity of NK cells. Thus, ES cells have
potential to generate NK-type cytotoxic lymphocytes in vitro in
addition to erythro-myeloid cells and pre-B cells, and both myeloid and
lymphoid cells seem to be derived from the CD34+
intermediate, on which VEGF may play an important role.
Blood, Vol. 91 No. 7 (April 1), 1998:
pp. 2283-2295
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G.-M. Zou, J.-J. Chen, M. C. Yoder, W. Wu, and J. D. Rowley
Knockdown of Pu.1 by small interfering RNA in CD34+ embryoid body cells derived from mouse ES cells turns cell fate determination to pro-B cells
PNAS,
September 13, 2005;
102(37):
13236 - 13241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, L. Verda, D.-A. Kim, Y. Oyama, K. Luo, and C. Link
Embryonic Stem Cells As an Alternate Marrow Donor Source: Engraftment without Graft-Versus-Host Disease
J. Exp. Med.,
April 5, 2004;
199(7):
895 - 904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cerdan, A. Rouleau, and M. Bhatia
VEGF-A165 augments erythropoietic development from human embryonic stem cells
Blood,
April 1, 2004;
103(7):
2504 - 2512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nakayama, C.-y. E. Han, L. Cam, J. I. Lee, J. Pretorius, S. Fisher, R. Rosenfeld, S. Scully, R. Nishinakamura, D. Duryea, et al.
A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage
Development,
January 1, 2004;
131(1):
229 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. de Pooter, S. K. Cho, J. R. Carlyle, and J. C. Zuniga-Pflucker
In vitro generation of T lymphocytes from embryonic stem cell-derived prehematopoietic progenitors
Blood,
September 1, 2003;
102(5):
1649 - 1653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nakayama, D. Duryea, R. Manoukian, G. Chow, and C.-y. E. Han
Macroscopic cartilage formation with embryonic stem-cell-derived mesodermal progenitor cells
J. Cell Sci.,
May 15, 2003;
116(10):
2015 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Senju, S. Hirata, H. Matsuyoshi, M. Masuda, Y. Uemura, K. Araki, K.-i. Yamamura, and Y. Nishimura
Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells
Blood,
May 1, 2003;
101(9):
3501 - 3508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Damert, L. Miquerol, M. Gertsenstein, W. Risau, and A. Nagy
Insufficient VEGFA activity in yolk sac endoderm compromises haematopoietic and endothelial differentiation
Development,
March 6, 2003;
129(8):
1881 - 1892.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Lian, M. Maeda, S. Lohwasser, M. Delcommenne, T. Nakano, R. E. Vance, D. H. Raulet, and F. Takei
Orderly and Nonstochastic Acquisition of CD94/NKG2 Receptors by Developing NK Cells Derived from Embryonic Stem Cells In Vitro
J. Immunol.,
May 15, 2002;
168(10):
4980 - 4987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nakayama, J. Lee, and L. Chiu
Vascular endothelial growth factor synergistically enhances bone morphogenetic protein-4-dependent lymphohematopoietic cell generation from embryonic stem cells in vitro
Blood,
April 1, 2000;
95(7):
2275 - 2283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Gupta, T. R. Oegema Jr, J. J. Brazil, A. Z. Dudek, A. Slungaard, and C. M. Verfaillie
Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins
Blood,
January 1, 2000;
95(1):
147 - 155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, and D. P. Carbone
Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo
Blood,
December 1, 1998;
92(11):
4150 - 4166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
